Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Special Access Program of NERLYNX (neratinib)

Trial Profile

A Special Access Program of NERLYNX (neratinib)

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Neratinib (Primary)
  • Indications Advanced breast cancer; Haematological malignancies; Solid tumours
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 28 Nov 2017 New trial record
    • 22 Nov 2017 According to a Specialised Therapeutics Asia media release, the company is planning to initiate this program in Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top